CureVac’s Lawsuit against Pfizer, BioNTech Picks Up Steam
Market News

CureVac’s Lawsuit against Pfizer, BioNTech Picks Up Steam

Back in the closing half of 2020, when finding a COVID-19 vaccine was all any biotech company could dream of, Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) were one of the first teams to actually pull it off. But the process hardly went off without a hitch, and now, CureVac (NASDAQ:CVAC) and its attempt to sue Pfizer and BioNTech over patent issues in the development of COVID-19 vaccines are carrying on that much more rapidly. CureVac added over 3% at the time of writing as a result.

With the latest court news, we find that CureVac’s move to transfer the current litigation has been approved by the federal district court of Massachusetts. The lawsuit is now in the hands of Virginia’s Eastern District, and a trial should follow at some point in 2024 as a result. CureVac alleged that Pfizer and BioNTech infringed on CureVac’s patents in nine different cases in order to create the COVID-19 vaccine.

More specifically, based on a statement from CureVac CEO Dr. Alexander Zehnder, Pfizer and BioNTech’s infringement of CureVac’s mRNA patents allowed Pfizer and BioNTech to more rapidly develop the COVID-19 vaccines. Thus, CureVac should be paid a portion of the vast sums of cash that Pfizer and BioNTech realized following the vaccine’s development and release. This isn’t the first time that such challenges have emerged. Moderna (NASDAQ:MRNA) actually sued the duo over Pfizer and BioNTech copying its own mRNA work.

A look at the last five trading days for CureVac stock shows a volatile trading pattern. While share prices are up since CureVac announced the suit was moving, share prices are actually lower now than they were a couple of days ago.

Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
RUT
Russell 2000
TNX
10-Yr-Bond
Bitcoin

Popular Articles